| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | JUNO THERAPEUTICS INCORPORATED | 1,229,512 | 36,898,000 | 28.17% | ||
| 2 | PARATEK PHARMACEUTICALS INC | 2,600,410 | 33,831,000 | 25.83% | ||
| 3 | Egalet Corp | 2,889,926 | 21,992,000 | 16.79% | ||
| 4 | FIBROGEN INC COM | 822,175 | 17,019,000 | 12.99% | ||
| 5 | Nabriva Therapeutics AG | 1,145,890 | 8,079,000 | 6.17% | ||
| 6 | ESSA Pharma | 1,696,969 | 4,667,000 | 3.56% | ||
| 7 | Pieris Pharmaceuticals | 1,848,984 | 3,384,000 | 2.58% | ||
| 8 | Proteon Therapeutics | 250,000 | 2,333,000 | 1.78% | ||
| 9 | Dicerna Pharmaceuticals | 223,457 | 1,314,000 | 1.00% | ||
| 10 | EDITAS MEDICINE INCORPORATED | 66,162 | 892,000 | 0.68% | ||
| 11 | CymaBay Therapeutics | 301,477 | 585,000 | 0.45% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-16-021058, filed 2016.11.02).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
